Posted by Michael Wonder on 10 Feb 2025
Big pharma steps up push for taxpayer-funded weight loss drugs
9 February 2025 - Novo Nordisk and Eli Lilly have asked the federal government to list their blockbuster weight-loss drugs on the Pharmaceutical Benefits Scheme, arguing funding the treatment will reduce a costly obesity crisis.
Novo Nordisk, the Danish pharmaceutical giant that makes Ozempic and Wegovy, used a submission to the government’s budget process to push for the inclusion of so-called GLP-1 drugs on the PBS for chronic weight management. It said not doing so would be more expensive in the long term.
